Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2014

01-05-2014 | Mini Review

Vitamin D and cancer: the promise not yet fulfilled

Author: Daniel D. Bikle

Published in: Endocrine | Issue 1/2014

Login to get access

Abstract

The negative association of the latitude where people live and the incidence of non cutaneous cancer in that population in North America have been demonstrated in many studies for many types of cancer. Since the intensity of UVB exposure decreases with increasing latitude, and UVB exposure provides the mechanism for vitamin D production in the skin, the hypothesis that increased vitamin D provides protection against the development of cancer has been proposed. This hypothesis has been tested in a substantial number of prospective and case control studies and in a few randomized clinical trials (RTC) assessing whether either vitamin D intake or serum levels of 25 hydroxyvitamin D (25OHD) correlate (inversely) with cancer development. Most of the studies have focused on colorectal, breast, and prostate cancer. The results have been mixed. The most compelling data for a beneficial relationship between vitamin D intake or serum 25OHD levels and cancer have been obtained for colorectal cancer. The bulk of the evidence also favors a beneficial relationship for breast cancer, but the benefit of vitamin D for prostate and skin cancer in clinical populations has been difficult to demonstrate. RTCs in general have been flawed in execution or too small to provide compelling evidence one way or the other. In contrast, animal studies have been quite consistent in their demonstration that vitamin D and/or its active metabolite 1,25 dihydroxyvitamin D (1,25(OH)2D) can prevent the development and/or treat a variety of cancers in a variety of animal models. Furthermore, 1,25(OH)2D has been shown to impact a number of cellular mechanisms that would be expected to underlie its anticancer effects. Thus, there is a dilemma—animal and cellular studies strongly support a role for vitamin D in the prevention and treatment of cancer, but the clinical studies for most cancers have not yet delivered compelling evidence that the promise from preclinical studies has been fulfilled in the clinic.
Literature
1.
F. Apperly, The relation of solar radiation to cancer mortality in North America. Cancer Res. 1, 191–195 (1941)
2.
C.F. Garland, F.C. Garland, Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. 9(3), 227–231 (1980)PubMed
3.
H.J. van der Rhee, E. de Vries, J.W. Coebergh, Does sunlight prevent cancer? A systematic review. Eur. J. Cancer 42(14), 2222–2232 (2006)PubMed
4.
W.B. Grant, Ecological studies of the UVB-vitamin D hypothesis. Anticancer Res. 32, p223–p236 (2012)
5.
Y. Ma et al., Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J. Clin. Oncol. 29(28), 3775–3782 (2011)PubMed
6.
L. Yin et al., Meta-analysis: serum vitamin D and colorectal adenoma risk. Prev. Med. 53(1–2), 10–16 (2011)PubMed
7.
M.L. McCullough et al., Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). Cancer Causes Control 14(1), 1–12 (2003)PubMed
8.
D.M. Freedman et al., Prospective study of serum vitamin D and cancer mortality in the United States. J. Natl. Cancer Inst. 99(21), 1594–1602 (2007)PubMed
9.
M. Huncharek, J. Muscat, B. Kupelnick, Colorectal cancer risk and dietary intake of calcium, vitamin D, and dairy products: a meta-analysis of 26,335 cases from 60 observational studies. Nutr. Cancer 61(1), 47–69 (2009)PubMed
10.
E. Cho et al., Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J. Natl. Cancer Inst. 96(13), 1015–1022 (2004)PubMed
11.
C. Carroll et al., Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis. Clin. Ther. 32(5), 789–803 (2010)PubMed
12.
J. Wactawski-Wende et al., Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 354(7), 684–696 (2006)PubMed
13.
E.L. Ding et al., Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women’s Health Initiative randomized trial. Int. J. Cancer 122(8), 1690–1694 (2008)PubMed
14.
15.
M. Rossi et al., Vitamin D intake and breast cancer risk: a case–control study in Italy. Ann. Oncol. 20(2), 374–378 (2009)PubMed
16.
M.H. Shin et al., Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J. Natl. Cancer Inst. 94(17), 1301–1311 (2002)PubMed
17.
J. Lin et al., Intakes of calcium and vitamin D and breast cancer risk in women. Arch. Intern. Med. 167(10), 1050–1059 (2007)PubMed
18.
P. Chen et al., Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res. Treat. 121(2), 469–477 (2010)PubMed
19.
20.
S. Gandini et al., Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer 128(6), 1414–1424 (2011)PubMed
21.
J. Ahn et al., Serum vitamin D concentration and prostate cancer risk: a nested case–control study. J. Natl. Cancer Inst. 100(11), 796–804 (2008)PubMedCentralPubMed
22.
R. Gilbert et al., Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22(3), 319–340 (2011)PubMed
23.
H.I. Scher et al., Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol. 29(16), 2191–2198 (2011)PubMed
24.
D.J. Hunter et al., Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women. Ann. Epidemiol. 2(3), 231–239 (1992)PubMed
25.
J.Y. Tang et al., Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control 21(3), 387–391 (2010)PubMedCentralPubMed
26.
M.M. Asgari et al., Association of prediagnostic serum vitamin D levels with the development of basal cell carcinoma. J. Invest. Dermatol. 130(5), 1438–1443 (2010)PubMedCentralPubMed
27.
M.J. Eide et al., Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort. Arch. Dermatol. 147(12), 1379–1384 (2011)PubMed
28.
H.L. Newmark et al., Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis 30(1), 88–92 (2009)PubMedCentralPubMed
29.
M. Froicu et al., A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol. Endocrinol. 17(12), 2386–2392 (2003)PubMed
30.
J. Kong et al., Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 294(1), G208–G216 (2008)PubMed
31.
G. Murillo et al., Actions of vitamin D are mediated by the TLR4 pathway in inflammation-induced colon cancer. J. Steroid Biochem. Mol. Biol. 121(1–2), 403–407 (2003)
32.
K. Yang et al., Dietary calcium and cholecalciferol modulate cyclin D1 expression, apoptosis, and tumorigenesis in intestine of adenomatous polyposis coli1638N/+ mice. J. Nutr. 138(9), 1658–1663 (2008)PubMed
33.
34.
W. Zheng et al., Inactivation of the vitamin D receptor in APC(min/+) mice reveals a critical role for the vitamin D receptor in intestinal tumor growth. Int. J. Cancer 130(1), 10–19 (2011)PubMedCentralPubMed
35.
S. Huerta et al., 1alpha,25-(OH)(2)-D(3) and its synthetic analogue decrease tumor load in the Apc(min) Mouse. Cancer Res. 62(3), 741–746 (2002)PubMed
36.
M. Lipkin, H.L. Newmark, Vitamin D, calcium and prevention of breast cancer: a review. J. Am. Coll. Nutr. 18(5 Suppl), 392S–397S (1999)PubMed
37.
G.M. Zinser, J. Welsh, Effect of vitamin D3 receptor ablation on murine mammary gland development and tumorigenesis. J. Steroid Biochem. Mol. Biol. 89–90(1–5), 433–436 (2004)PubMed
38.
G.M. Zinser, J. Welsh, Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis 25(12), 2361–2372 (2004)PubMed
39.
K. VanWeelden et al., Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 139(4), 2102–2110 (1998)PubMed
40.
L.L. Ooi et al., Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 70(5), 1835–1844 (2010)PubMed
41.
K. El Abdaimi et al., The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 60(16), 4412–4418 (2000)PubMed
42.
V. Bhatia et al., EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol. Cancer Ther. 8(7), 1787–1798 (2009)PubMedCentralPubMed
43.
Y. Zheng et al., Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 71(9), 1012–1021 (2011)PubMed
44.
S. Mordan-McCombs et al., Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J. Steroid Biochem. Mol. Biol. 121(1–2), 368–371 (2010)PubMed
45.
A.V. Krishnan et al., The role of vitamin D in cancer prevention and treatment. Endocrinol. Metab. Clin. North Am. 39(2), 401–418 (2010). (table of contents)PubMed
46.
I. Chung et al., Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 69(3), 967–975 (2009)PubMedCentralPubMed
47.
G.M. Zinser, J.P. Sundberg, J. Welsh, Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis 23(12), 2103–2109 (2002)PubMed
48.
A.K. Indra et al., Malignant transformation of DMBA/TPA-induced Papillomas and Nevi in the skin of mice selectively lacking retinoid-X-receptor alpha in epidermal keratinocytes. J. Invest. Dermatol. 127, 1250–1260 (2007)PubMed
49.
T.I. Ellison et al., Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. J. Invest. Dermatol. 128, 2508–2517 (2008)PubMed
50.
A.E. Teichert et al., Overexpression of hedgehog signaling is associated with epidermal tumor formation in vitamin D receptor-null mice. J. Invest. Dermatol. 131(11), 2289–2297 (2011)PubMedCentralPubMed
51.
R. Gupta et al., Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. J. Invest. Dermatol. 127(3), 707–715 (2007)PubMed
52.
G. Hager et al., 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 121(1), 103–109 (2001)PubMed
53.
H.G. Palmer et al., Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 63(22), 7799–7806 (2003)PubMed
54.
E.S. Yang, K.L. Burnstein, Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J. Biol. Chem. 278(47), 46862–46868 (2003)PubMed
55.
X. Wang et al., MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 8(5), 736–741 (2009)PubMedCentralPubMed
56.
G. Liu, X. Hu, S. Chakrabarty, Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int. J. Cancer 126(3), 631–639 (2010)PubMed
57.
B.S. An et al., Stimulation of Sirt1-regulated FoxO protein function by the ligand-bound vitamin D receptor. Mol. Cell Biol. 30(20), 4890–4900 (2010)PubMedCentralPubMed
58.
M.B. Meyer, P.D. Goetsch, J.W. Pike, VDR/RXR and TCF4/beta-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol. Endocrinol. 26(1), 37–51 (2012)PubMedCentralPubMed
59.
K.W. Colston et al., Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J. Mol. Endocrinol. 20(1), 157–162 (1998)PubMed
60.
H. Huynh, M. Pollak, J.C. Zhang, Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int. J. Oncol. 13(1), 137–143 (1998)PubMed
61.
D.M. Peehl et al., Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J. Steroid Biochem. Mol. Biol. 92(3), 131–141 (2004)PubMed
62.
S. Swami et al., Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. 80(1), 49–62 (2003)PubMed
63.
L. Yang et al., Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J. Cell Physiol. 188(3), 383–393 (2001)PubMed
64.
M. Aszterbaum et al., Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Invest. Dermatol. 110(6), 885–888 (1998)PubMed
65.
J.B. Cordero et al., 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J. Biol. Chem. 277(41), 38965–38971 (2002)PubMed
66.
K.R. McGaffin, S.A. Chrysogelos, Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. J. Mol. Endocrinol. 35(1), 117–133 (2005)PubMed
67.
S.W. Byers et al., Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev. Endocr. Metab. Disord. 13(1), 31–38 (2011)
68.
D.D. Bikle, The vitamin D receptor: a tumor suppressor in skin. Discov. Med. 11(56), 7–17 (2011)PubMed
69.
P. Ordonez-Moran et al., The effects of 1,25-dihydroxyvitamin D3 on colon cancer cells depend on RhoA-ROCK-p38MAPK-MSK signaling. J. Steroid Biochem. Mol. Biol. 121(1–2), 355–361 (2010)PubMed
70.
O. Aguilera et al., The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 28(9), 1877–1884 (2007)PubMed
71.
N. Pendas-Franco et al., DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D3. Oncogene 27(32), 4467–4477 (2008)PubMed
72.
G.D. Diaz et al., Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 60(8), 2304–2312 (2000)PubMed
73.
L. Pan et al., Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrate-induced and 5-aza-2′-deoxycytidine-induced PTEN upregulation. FEBS J. 277(4), 989–999 (2010)PubMed
74.
S. Kizildag, H. Ates, S. Kizildag, Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann. Hematol. 89(1), 1–7 (2009)PubMed
75.
G.E. Weitsman et al., Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. Ann. N. Y. Acad. Sci. 1010, 437–440 (2003)PubMed
76.
G.E. Weitsman et al., Vitamin D sensitizes breast cancer cells to the action of H2O2: mitochondria as a convergence point in the death pathway. Free Radic. Biol. Med. 39(2), 266–278 (2005)PubMed
77.
I.N. Sergeev, Vitamin D and cellular Ca2+ signaling in breast cancer. Anticancer Res. 32(1), 299–302 (2012)PubMed
78.
M. Hoyer-Hansen et al., Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ. 12(10), 1297–1309 (2005)PubMed
79.
S.E. Freeman et al., Wavelength dependence of pyrimidine dimer formation in DNA of human skin irradiated in situ with ultraviolet light. Proc. Natl. Acad. Sci. USA 86(14), 5605–5609 (1989)PubMedCentralPubMed
80.
A. Besaratinia et al., DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene. Proc. Natl. Acad. Sci. USA 102(29), 10058–10063 (2005)PubMedCentralPubMed
81.
M.R. Hussein, Ultraviolet radiation and skin cancer: molecular mechanisms. J. Cutan. Pathol. 32(3), 191–205 (2005)PubMed
82.
S.K. Demetriou et al., Vitamin D receptor mediates DNA repair and is UV inducible in intact epidermis but not in cultured keratinocytes. J. Invest. Dermatol. 132(8), 2097–2100 (2012)PubMedCentralPubMed
83.
J.G. Mabley et al., Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D. Int. J. Mol. Med. 19(6), 947–952 (2007)PubMedCentralPubMed
84.
V. Fedirko et al., Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev. 19(1), 280–291 (2010)PubMedCentralPubMed
85.
P.R. Moll et al., Expression profiling of vitamin D treated primary human keratinocytes. J. Cell. Biochem. 100(3), 574–592 (2007)PubMed
86.
N. Akutsu et al., Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol. Endocrinol. 15(7), 1127–1139 (2001)PubMed
87.
B.Y. Bao et al., Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int. J. Cancer 122(12), 2699–2706 (2008)PubMed
88.
E. Kallay et al., Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 22(9), 1429–1435 (2001)PubMed
89.
K. Muller-Decker, G. Furstenberger, The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol. Carcinog. 46(8), 705–710 (2007)PubMed
90.
A. Greenhough et al., The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30(3), 377–386 (2009)PubMed
91.
D.J. Mantell et al., 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ. Res. 87(3), 214–220 (2000)PubMed
92.
M. Ben-Shoshan et al., 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol. Cancer Ther. 6(4), 1433–1439 (2007)PubMed
93.
V. Sung, D. Feldman, 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol. Cell. Endocrinol. 164(1–2), 133–143 (2000)PubMed
94.
W. Liu et al., Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action. Lab. Invest. 91(1), 147–156 (2011)PubMed
95.
B.Y. Bao, J. Yao, Y.F. Lee, 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27(9), 1883–1893 (2006)PubMed
96.
D. Matusiak et al., Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol. Biomarkers Prev. 14(10), 2370–2376 (2005)PubMed
97.
M.J. Larriba et al., Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis 30(8), 1459–1468 (2009)PubMed
98.
R. Maruyama et al., Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res. 66(9), 4574–4583 (2006)PubMed
99.
T. Mohri et al., MicroRNA regulates human vitamin D receptor. Int. J. Cancer 125(6), 1328–1333 (2009)PubMed
100.
J.Y. Hsu et al., Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61(7), 2852–2856 (2001)PubMed
101.
M.G. Anderson et al., Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol. 57(2), 234–240 (2006)PubMed
Metadata
Title
Vitamin D and cancer: the promise not yet fulfilled
Author
Daniel D. Bikle
Publication date
01-05-2014
Publisher
Springer US
Published in
Endocrine / Issue 1/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0146-1

Other articles of this Issue 1/2014

Endocrine 1/2014 Go to the issue

Endocrine imaging

Metastatic small cell neuroendocrine carcinoma of the pelvic floor

Original Article

Ethanol ablation of benign thyroid cysts and predominantly cystic thyroid nodules: factors that predict outcome

Meta-Analysis

Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis

Viewpoint

Unhealthy diets: a common soil for the association of metabolic syndrome and cancer

Original Article

Obesity modifies expression profiles of metabolic markers in superficial and deep subcutaneous abdominal adipose tissue depots

Editorial

99mTc-MIBI imaging in thyroid nodules: Is it useful?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits